Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
02 Février 2024 - 8:28AM
Settlement of the combination of Novozymes and Chr. Hansen Holding
successfully completed
Settlement of the combination of
Novozymes and Chr. Hansen Holding successfully
completed
February 2, 2024Company announcement No. 07 |
On January 29, 2024, following the satisfaction
of all conditions precedent, the combination of Novozymes A/S
("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of
a statutory merger of the two companies (the "Combination") was
successfully completed. Reference is made to Novozymes' company
announcement no. 2 of January 29, 2024. As previously announced,
the name of the combined company will be Novonesis.
Settlement of the Combination
completedThe settlement of the Combination has now been
successfully completed by the exchange of all shares of Chr. Hansen
for 187,298,646 new Novozymes B-shares of nominally DKK 2 each
(374,597,292 new Novozymes B-shares of nominally DKK 1) (the
"Merger Consideration Shares") under the existing ISIN code
DK0060336014 and the cash payment in lieu of fractional
entitlements to Merger Consideration Shares via Euronext Securities
Copenhagen has been initiated.
Eligible former shareholders of Chr. Hansen (the
"Chr. Hansen Shareholders"), excluding Novo Holdings A/S ("Novo
Holdings"), have received 1.5326 Merger Consideration Shares in
exchange for each Chr. Hansen share that they held, and Novo
Holdings has received 1.0227 Merger Consideration Shares in
exchange for each Chr. Hansen share held with respect to Novo
Holdings' holding of 28,983,112 Chr. Hansen shares and 1.5326
Merger Consideration Shares in exchange for each Chr. Hansen share
held exceeding 28,983,112.
The Merger Consideration Shares issued have been
admitted to trading and official listing on Nasdaq Copenhagen A/S
on January 31, 2024, under the symbol "NZYM B" and the permanent
ISIN code DK0060336014.
Chr. Hansen Shareholders restricted from receiving
shares in the Combination
As further described in the exemption document,
certain Chr. Hansen Shareholders with a registered address in, or
who are resident or otherwise located in, or who are organized
under the laws of certain jurisdictions, the ability to participate
in the Combination and receive new B-shares has been restricted by
the laws of such other jurisdictions (each a "Restricted
Shareholder").
For such Restricted Shareholders only, the
combined company will procure that the new B-shares that would
otherwise be attributable to such Restricted Shareholders will be
sold by Nordea Danmark, Filial af Nordea Bank Abp, Finland acting
on behalf of the combined company, in a vendor placement (via
Nasdaq Copenhagen or other trading venues in one or more tranches
and outside the U.S. and other restricted jurisdictions) (the
"Vendor Placement") and the cash proceeds from the Vendor Placement
will be distributed in DKK to the Restricted Shareholders via a
corporate action in Euronext as soon as practicably possible
following completion of the Vendor Placement. Other shareholders in
the combined company cannot participate in the Vendor
Placement.
For further information on the Vendor Placement,
reference is made to the exemption document available at
www.power-with-biology.com.
Transaction websiteFor
additional information, visit www.power-with-biology.com.
Contact information |
Investor
Relations |
|
|
Tobias Bjorklund |
+45 3077 8682 |
tobb@novonesis.com |
Anders Enevoldsen |
+45 5350 1453 |
adev@novonesis.com |
Media
Relations |
|
|
Lina Danstrup |
+45 3077 0552 |
lind@novonesis.com |
|
|
|
- 2024_07_Settlement_Completed
Novonesis AS (TG:NZM2)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Novonesis AS (TG:NZM2)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024